Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: GlobeNewswire
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® - - Ad-hoc analyses of pancreatic cancer population subgroups suggest meaningful improvement in median overall survival (OS) for patients treated with Alpha DaRT after prior therapy, compared to previously published studies of alternative monotherapies, across all analyzed subgroups – - Investigational Device Exemption (IDE) received from the FDA to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with metastatic pancreatic cancer - - Approval received from France’s Ministry of Health to commence French multicenter clinical trial of Alpha DaRT alongside capecitabine for patients with locally advanced pancreatic cancer - - In the first eight patients of a combination trial of Alpha DaRT with a checkpoint inhibitor (pembrolizumab) for recurrent unresectable or metastatic head and neck squa
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State UniversityGlobeNewswire
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI SymposiumGlobeNewswire
DRTS
Earnings
- 11/20/25 - Beat
DRTS
Sec Filings
- 12/18/25 - Form 6-K
- 12/11/25 - Form 144
- 12/9/25 - Form 6-K
- DRTS's page on the SEC website